Overview

* DocGo Q2 2025 revenue falls 51% yr/yr but beats analyst expectations, per LSEG data

* Adjusted EBITDA loss for Q2 beats estimates, per LSEG data

* Company reiterates 2025 revenue and adjusted EBITDA guidance

Outlook

* DocGo ( DCGO ) expects full-year 2025 revenue of $300-$330 mln

* Company anticipates full-year 2025 adjusted EBITDA loss of $20-$30 mln

* DocGo ( DCGO ) plans to enter more states in payer-provider vertical by 2026

* Company expects increased revenue in medical transportation in H2 2025

Result Drivers

* CASH BALANCE INCREASE - Total cash balance rose to $128.7 mln due to collections on migrant-related receivables, per CFO Norm Rosenberg

* COST REDUCTION - Significant cuts to corporate overhead expected to save $10 mln annually, with further reductions planned

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Beat $80.40 $77.60

Revenue mln mln (7

Analysts

)

Q2 Net -$13.30

Income mln

Q2 Beat -$6.10 -$7.14

Adjusted mln mln (7

EBITDA Analysts

)

Q2 Gross 26.7%

Margin

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the healthcare facilities & services peer group is "buy"

* Wall Street's median 12-month price target for DocGo Inc ( DCGO ) is $3.00, about 53% above its August 6 closing price of $1.41

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)